Results 241 to 250 of about 24,517 (327)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

One health strategic planning: multi-criteria decision analysis to prioritize rabies interventions in Burkina Faso. [PDF]

BMC Public Health
Savadogo M, Yameogo PSA, Irabor TO, Bada-Alambédji R, Antoine-Moussiaux N.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Response to letter to editor. [PDF]

Menopause
Bluming AZ, Hodis HN, Langer RD.
europepmc   +1 more source

['الاشتراط لمصلحة الغیر', 'The Stipulation for the Benefit of Others']

الرافدین للحقوق
Falah Ali, Akram Mahmod
doaj  

Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial. [PDF]

BMC Cancer
Sarfraz Z, Ozair A, Bardhan M, Starosciak AK, Perche DC, Hodgson LC, Odia Y, Mehta MP, Kotecha R, McDermott MW, Maharaj A, Leon ACS, Mahtani R, Ahluwalia MS.   +13 more
europepmc   +1 more source

Social Work Workforce, Licensing, and Hawai'i: An Overview. [PDF]

Hawaii J Health Soc Welf
Arndt RG, Bersamira CS, Kreif TM, Stotzer RL.   +3 more
europepmc   +1 more source

Laying a Strong Foundation with a Novel "Basal-Bolus" Point of Care Ultrasound Curriculum for Internal Medicine Residents. [PDF]

POCUS J
Finn EM, Stephens JR, Spangler H, Fennell M, Hardy O, Dancel R.   +5 more
europepmc   +1 more source

On Ontology by Stipulation

openaire   +1 more source